Human herpesvirus 6 (HHV-6) is a recently described T-cell pathogen whose medical relevance and molecular biology are just beginning to be addressed. As a first look at the regulation of viral genes, control of the HHV-6 DNA polymerase promoter was examined. Polymerase gene transcription in HHV-6-infected cells was found to initiate from a single site located 115 bases upstream of the translation start codon. A polymerase promoter-chloramphenicol acetyltransferase reporter gene construct failed to be expressed in uninfected T cells but was highly active in HHV-6-infected cells. Mutational data indicated that the polymerase promoter is TATA-less. Mutational analysis also revealed that the major upstream promoter regulatory element required for transcriptional activity in HHV-6-infected cells is a palindromic ATF/CREB transcription factor binding site. The significance of this site for promoter induction was further demonstrated by the fact that the polymerase ATF/CREB element, when appended to a heterologous basal promoter, is highly responsive to HHV-6 infection. Two protein complexes were found to bind in a specific manner to the ATF/CREB motif in both uninfected and HHV-6-infected T-cell nuclear extracts. Site-specific mutation of the ATF/CREB site resulted in loss of protein binding as well as loss of promoter activity in HHV-6-infected cells.
Human herpesvirus 6 (HHV-6) was first isolated in 1986 from the peripheral blood lymphocytes of patients with AIDS and with lymphoproliferative disorders (35) . The virus was subsequently shown to be ubiquitous in the healthy adult population, with seropositivity rates in excess of 80% (5) . Initial infection generally occurs between 1 and 3 years of age, and thereafter latent virus is thought to be carried for life (22) . has been shown to cause exanthem subitum (roseola infantum), a benign rash and fever of early childhood, and is likely to be responsible for some cases of heterophile-negative infectious mononucleosis (37, 43) .
The virus is predominantly tropic for CD4+ T lymphocytes but can infect several other cell types as well (2, 27) . Since CD4 is the cellular receptor utilized by human immunodeficiency virus type 1 (HIV-1), a potential interaction between these two viruses has been investigated. Coinfection of T cells with HIV-1 and HHV-6 results in increased replication of HIV-1 in vitro (25) . Also, HHV-6 infection of either CD8+ T cells or CD3 -natural killer cells causes upregulation of CD4, rendering these cells susceptible to HIV-1 infection (24, 26) . is shed intermittently in the saliva of healthy adults, without associated changes in antibody titer (22) . This reactivation is a likely source of person-to-person transmission. reactivation, while generally asymptomatic in the healthy population, may have serious consequences in immunosuppressed individuals. In bone marrow transplant patients, is associated with suppression of marrow function, and in vitro studies indicate that HHV-6 can impair macrophage maturation (4) .
HHV-6 has a double-stranded DNA genome of approximately 170 kb, consisting of a unique long region flanked by 10-kb direct repeats (28) . The virus is predicted to encode more than 70 proteins. Partial sequence analysis has revealed that HHV-6 is most closely related to human cytomegalovirus (HCMV) and that the genomic organization of the unique long regions of and HCMV are largely collinear (19, 32) .
The DNA polymerase gene of HHV-6 has been cloned and characterized (39) ; however, little is known about the regulation of this or any other HHV-6 gene. In this study, the HHV-6 DNA polymerase promoter region was analyzed. It was found that a promoter-CAT construct is not expressed in uninfected T cells but is highly upregulated following HHV-6 infection. The most important promoter upstream regulatory element has been identified as a palindromic binding site for the ATF/CREB (hereafter referred to as ATF) family of transcription factors. This element can strongly confer HHV-6 inducibility to a heterologous promoter.
MATERIALS AND METHODS
Cells and virus. The HSB-2 human T-cell line was grown in RPMI 1640 (Gibco) supplemented with 10% fetal calf serum and antibiotics (2) . HSB-2 cells were infected with the HHV-6 strain GS, and infected cell cultures were maintained by addition of uninfected HSB-2 cells to infected cells displaying cytopathic effect (15) .
DNA sequence analysis. Sequencing of double-stranded plasmid DNA was performed by the dideoxynucleotide chain termination method using synthetic oligonucleotide primers (36) . Sequence data were analyzed by using the University of Wisconsin Genetics Computer Group sequence analysis package and the GenEMBL and Tf sites data bases (7) .
Primer extension. Total cytoplasmic RNA was isolated as previously described (33) from both uninfected and HHV-6-infected HSB-2 cells. A 20-base oligonucleotide (5'-CCTGTC TATCAAACTAGGTT-3') complementary to thepolymerase 5' untranslated region was 32P end labelled, and 10 cpm of the oligonucleotide was ethanol precipitated along with 20 Electrophoretic mobility shift assay. Probes were generated by32P end labelling of double-stranded blunt-ended oligonucleotides. The ATF oligonucleotide was the same as that used for the heterologous promoter construct: top strand, 5'-GGG TATGGCTGACGTCAGTGGGCAAG-3'. Competitions were performed with cold double-stranded blunt-ended oligonucleotides. The ATF mutant competitor was (top strand) 5'-GGGTATGGCTGTTAACAGTGGGCAAG-3'. This topstrand oligonucleotide was used to introduce the ATF mutation into the promoter-CAT plasmid. Binding reaction mixtures (20,ul) contained 5,ug of nuclear protein, 10 mM HEPES (pH 7.9), 60 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 10% glycerol, 1 ,ug of poly(dI-dC), 0.2 ng of labelled probe, and competitor oligonucleotide if applicable. Reaction mixtures were incubated for 5 min at room temperature without probe to allow the competitor to bind, and then probe was added and the incubation was continued for 20 min at 30°C. Samples were separated on 4% nondenaturing polyacrylamide gels in 0.5 x Tris-borate EDTA buffer at 4°C. Autoradiography was performed as described above. RESULTS HHV-6 DNA polymerase gene transcription initiates at a single site. The nucleotide sequence of the DNA polymerase gene of HHV-6 (39) was used to design probes for S1 and primer extension analyses (Fig. 1) . For Si analysis, the probe consisted of single-stranded 32P-end-labelled DNA which spanned the region from 305 bp upstream to 78 bp downstream of the predicted translation start codon of the polymerase gene. The Si probe protected a 194-nucleotide (nt)-length RNA from HHV-6-infected T cells but not from RNA from uninfected T cells. This indicates that polymerase gene transcription initiates 115 nt upstream of the translation start codon in HHV-6-infected cells. For primer extension analysis, the probe used was a 32P-end-labelled oligonucleotide with the 5' terminus located 45 nt upstream of the polymerase translation start codon. A single product of 71 nt, specific to HHV-6-infected cells, was observed, confirming the location of the polymerase gene transcription start site at 115 nt upstream of the translation start codon.
A polymerase promoter-CAT construct is highly upregulated in HHV-6-infected cells. An HHV-6 polymerase promoter DNA fragment containing sequences from -524 to + 115 relative to the start site of transcription was cloned upstream of the CAT reporter gene coding region. The control plasmid was the same CAT vector without any HHV-6 sequences present. These constructs were tested by transfection into the HSB-2 T-cell line followed by the addition of uninfected T cells or HHV-6-infected T cells as a source of virus (Fig. 2) . Following transfection, the control plasmid produced undetectable CAT activity levels (<1% conversion) when uninfected cells were added and was upregulated only slightly when HHV-6-infected cells were added. After transfection of the polymerase promoter-CAT construct, CAT activity was also undetectable when uninfected cells were added. However, when polymerase promoter-CAT-transfected cells were cocul- were sized by using a sequencing ladder which was run alongside the assay products (not shown). A schematic of the Si and primer extension assays is depicted below. Arrow, transcription start site. *, 32P-end-label.
tivated with HHV-6-infected cells, a dramatic increase in activity to levels which are 50-fold greater than that of the control plasmid was observed. Thus, the HHV-6 DNA polymerase promoter is inactive in uninfected T cells but is highly induced following infection by HHV-6. The polymerase promoter is TATA-less. The polymerase promoter sequence is shown in Fig. 3 mutation as shown in Fig. 4 (AT-rich mutants A, B, and C) . The mutants were then tested by transfection into T cells followed by cocultivation with uninfected or HHV-6-infected cells. As with the wild-type promoter, these constructs showed undetectable CAT levels in uninfected cells (data not shown). None of these mutations caused a significant decrease in promoter activity in HHV-6-infected cells, since the variation in CAT activity between experiments, while usually less than 10%, occasionally reached 15%. This result strongly implies that the HHV-6 polymerase promoter is TATA-less.
The predominant upstream promoter element is the ATF site. In order to assess the contribution of the CAAT box, purine box, ATF site, or any other upstream sequences to polymerase promoter activity, a 5' deletion series was constructed in the polymerase promoter-CAT plasmid. The deletion constructs were tested by transfection into T cells followed by cocultivation with uninfected or HHV-6-infected cells (Fig.  5) . In uninfected cells, all constructs showed undetectable CAT levels (data not shown). This ruled out the existence of a negative upstream regulatory sequence which might have accounted for the lack of promoter expression in uninfected cells. In HHV-6-infected cells, deleting sequences from -524 to -97 relative to the transcription start site did not affect CAT activity. Thus, the CAAT motif at -191 is not involved in promoter activation in infected cells. Deleting 10 bases further, to -87, however, gave an approximately 30% (1.4-fold) drop in promoter activity. This deletion removes the 5' end of the purine box. Removing the remainder of the purine box, to -77, did not decrease activity any further. However, deleting the entire ATE site, to -67, resulted in a dramatic 13-fold drop in promoter activity. Deletion to +33 reduced activity twofold, to the background level obtained with the promoterless CAT plasmid. Thus, the ATF site appears to be the major upstream regulatory element, with the purine box playing a minor role. Fig. 3 . The data shown are the averages of three experiments. activity was further assessed by point mutation (Fig. 4) . For analysis of the purine box, two mutants were generated. Mutant A has 4 bases substituted in the 5' end of the purine motif, and mutant B has 7 bases changed in the 3' end. Relative to the full-length wild-type promoter, mutants A and B gave 7 and 14% decreases in promoter activity, respectively, in HHV-6 infected cells, which is within the observed experimental variation in CAT activity. Therefore, by point mutational analysis, the purine box does not appear to be important for promoter function. There are two possible explanations for the finding that deletion of the purine box (Fig. 5, -87 construct) produced a greater reduction in activity than did nucleotide substitutions. First, the bases critical to purine box function may not have been mutated in construct A or B (Fig.  4) . Alternatively, the decrease in CAT levels seen with the 5' deletion to -87 may have resulted from a negative effect on the ATF site due to the juxtaposition of novel 5' sequences rather than from removal of the purine box. Regardless, the purine box does not appear to contribute in a major way to promoter activity. By contrast, the predominant role of the ATF site for promoter activation in HHV-6-infected cells was confirmed by point mutational analysis. Changing the four central bases in the ATF palindrome caused an 88% (8.3-fold) drop in promoter strength (Fig. 4) .
Sequences downstream of the transcription start site are not required for promoter activity. To test for the presence of promoter regulatory sequences downstream of the transcription start site, a 3' deletion series was constructed in the polymerase promoter-CAT plasmid and tested by transfectioninfection (Fig. 5, bottom) . These constructs were also inactive in uninfected cells (data not shown). Deleting from + 115 to +63 resulted in an approximately 30% increase in activity in HHV-6-infected cells. Since the length of the mRNA leader is altered by the 3' deletions, this relatively small change in CAT activity may be due to an effect on translation efficiency rather than on transcription. Alternatively, we cannot rule out the possibility that this deletion removed a weak negative control element. Further removal of sequences, to + 13, had no Schematics of the TK-CAT constructs are shown with CAT activities in uninfected and HHV-6-infected cells to the right. TK-CAT control plasmid activities in uninfected and HHV-6-infected cells were independently normalized to 1. Uninfected cell CAT assays were incubated for 3 h at 37°C and quantitated by densitometry after a 1-week exposure to X-ray film. The HHV-6-infected samples were incubated for 1 h at 37°C and quantitated as described in Materials and Methods. The data shown are the averages of three experiments. significant effect on promoter strength. We conclude that sequences downstream of + 13 relative to the start site of transcription do not contain any important positive regulatory signals for promoter expression in HHV-6-infected cells. Deletion to -57, which should remove sequences involved in basal transcription, diminished activity almost to promoterless CAT background levels, as expected.
The ATF site can confer HHV-6 responsiveness to a heterologous promoter. Given the importance of the ATF element for promoter activation, we tested whether this site, in the absence of other polymerase promoter sequences, could confer inducibility to HHV-6 infection. The polymerase promoter ATF site, two copies of the purine box (GA box), or both elements in their natural orientations were placed upstream of the HSV-1 TK basal promoter (construct ATF-TK-CAT, GA x 2-TK-CAT, or GA-ATF-TK-CAT, respectively) (Fig. 6) . Two copies of the purine box were inserted because of the low level of activity associated with this element. The TK promoter sequences in these constructs included only the TATA box and transcription initiation regions, with no TK upstream activating elements present. The control TK-CAT construct contained no HHV-6 sequences upstream of the TK basal promoter. These plasmids were tested by transfection into T cells followed by cocultivation with uninfected or HHV-6-infected cells. The higher activity of the TK basal promoter compared with the natural polymerase promoter allowed the quantitation of CAT activities in uninfected cells for the TK constructs. In uninfected cells, addition of the ATF site, purine box, or both to the TK basal promoter had little effect on activity. Strikingly, however, in HHV-6-infected cells, addition of the ATF site upstream of the TK basal promoter (ATF-TK-CAT) resulted in 23-fold-increased activity over that of the control (TK-CAT) plasmid. The construct containing two copies of the purine box (GA x 2-TK-CAT) showed only a twofold induction over control plasmid activity in infected cells. The construct GA-ATF-TK-CAT was used to examine the ability of the purine box to cooperate with the ATF site for activation of the TK basal promoter. This construct, which contained both the ATF site and the purine box linked together exactly as in the natural polymerase promoter, produced essentially the same 24-fold induction over control plasmid activity in infected cells as did the ATF-TK-CAT plasmid, which contained only the ATF site. This indicates a lack of cooperativity between the two polymerase promoter elements in the context of the TK basal promoter and suggests that the purine box does not function under these conditions. Consistent with the mutagenesis results, this analysis suggests that the purine box plays a minor role in promoter activation. These results also confirm that the ATF site is a strong positive element in HHV-6-infected cells and demonstrate that this site is sufficient to confer HHV-6 inducibility to a heterologous basal promoter.
The ATF site specifically binds two protein complexes. To analyze protein binding to the ATF site, a double-stranded oligonucleotide containing the polymerase promoter ATF element was labelled for use in bandshift assays (Fig. 7) . Two protein complexes, Cl and C2, were observed in both uninfected-and infected-cell nuclear extracts. Shorter exposures of the autoradiogram shown in Fig. 7 revealed that (13, 20, 31) . ATF sites are capable of binding homo-or heterodimers of proteins belonging to the large family of cellular transcription factors referred to as bZIP, for basicregion leucine zipper proteins, which includes the CREB/ATF, Fos/Jun, and C/EBP subfamilies (30) . The particular constituents of the protein dimers determine the DNA-binding specificity and whether binding will result in activation or repression. An additional level of regulation occurs through posttranslational modification, such as phosphorylation, which has been shown to affect either the DNA-binding or the activation abilities of several bZIP proteins (1, 10) .
In this study, mobility shift assays have revealed that two protein complexes bind specifically to the HHV-6 polymerase ATF element. The presence of two complexes suggests the potential involvement of multiple bZIP proteins in regulatory interactions with the ATF site. In this regard, our preliminary results indicate that the complex Cl, but not C2, contains the bZIP protein ATF-2 or an ATF-2-like factor, as an antiserum directed against ATF-2 can block formation of Cl in mobility shift assays. The fact that the same two ATF-binding complexes are observed in both uninfected and HHV-6-infected cells but promoter activity is only observed in infected cells suggests several possible, non-mutually exclusive ways in which the ATF-binding proteins could be involved in promoter regulation. First, promoter induction may be mediated through interactions between the basal transcription machinery, ATFbinding proteins, and viral transactivators. Adenovirus ElA and HSV-1 VP16, among others, are thought to transcriptionally transactivate promoters by bridging upstream binding factors to the basal machinery (23, 38, 41) . Interestingly, ElA has been shown to interact directly with ATF-2 and the basal factor TBP (6, 9) . Second, transcriptional activation ability of the ATF-binding factor(s) may be induced by posttranslational modification, which may not affect migration of the complexes. Third, a change in bZIP dimerization partners is possible since many family members have similar molecular weights and thus may migrate indistinguishably in mobility shift assays. Finally, alterations in chromatin structure may occur during infection such that the polymerase ATF site becomes accessible for factor binding. Indeed, the HCMV immediate-early proteins appear to be capable of upregulating transcription in vitro by reversing repression resulting from assembly of DNA templates into chromatin (17) . It is to be noted that in our mobility shift assays, the ATF probe is not likely to be packaged as chromatin and therefore would be available for protein binding in both infected and uninfected cell extracts.
The HHV-6 DNA polymerase promoter appears to be TATA-less, as mutation of any of the AT-rich motifs in the -30 region was without effect. Many TATA-less promoters have been described, most of which have initiator elements encompassing the transcription start site (34, 42) . These elements determine start site placement, as does TFIID with TATA-containing promoters. Initiators have been grouped according to sequence conservation; however, none of these sequences could be identified in the polymerase promoter initiation region. Nevertheless, our 3' deletion results suggest that the basal promoter resides between -57 and + 13 relative to the transcription start site.
Interestingly, the HCMV DNA polymerase promoter, which otherwise has no sequence homology with the HHV-6 polymerase promoter (18) , contains an ATF-like motif, TGA CGTCG, at approximately the same position ( -85 bp) as the HHV-6 promoter ATF site, TGACGTCA (-70 bp). Whether the HCMV ATF-like site is virally inducible has yet to be determined. The only human herpesvirus DNA polymerase promoter which has been previously mapped by deletion studies is that of Epstein-Barr virus (8 
